ACTH=Adrenocorticotrophic hormone MINOR= mitogen inducible orphan nuclear receptor NGF1-B= nerve growth factor 1 beta NOR-1= neuron derived orphan receptor 1 
BACKGROUND
Targeting ligand activated steroid nuclear receptors is an important established cancer therapy. Orphan nuclear receptors are similar to steroid nuclear receptors as they act as transcription factors to modulate down-stream gene expression. However, orphan nuclear receptors have no known natural ligand(s). These intriguing receptors comprise over half the total number of nuclear receptors. NR4A orphan nuclear receptors NR4A1 (Nur77; TR3; NGFB-1), NR4A2 (NURR1) and NR4A3 (NOR-1; MINOR)) are thought to be incapable of classic ligand binding due to bulky ligand binding domains, unlike "adopted" receptors, e.g. PPAR-γ (NR1C3), where putative ligands have since been discovered.
Diverse and paradoxical transcriptional and direct roles have been described for these receptors; physiological functions of NR4A receptors are context and tissue specific. NR4A receptors have emerged as important molecular switches in processes associated with carcinogenesis, including apoptosis, DNA repair, proliferation, migration, inflammation, metabolism and angiogenesis. 
NR4A receptors and Cancer

Apoptosis
Inhibition of Apoptosis
NR4A receptors can promote cell growth and survival, activating transcription of downstream anti-apoptotic and pro-proliferative genes.
Physiologically, NR4A2 is essential for dopaminergic neuronal survival in the central nervous system, and reduced NR4A2 is implicated in the DNA repair action of NR4A receptors is not dependent on their transcriptional activity, but rather due to a direct interaction at the DNA repair site, the precise mechanisms of which remain incompletely understood. (18) 
NR4A Receptors and Chromosomal Translocations
Chromosomal translocation of NR4A receptors can lead to oncogenic conversion. For example, translocations involving NR4A3 in extra skeletal myxoid chondrosarcoma, most commonly between Ewing's Sarcoma Region-1(EWS) and NR4A3 t(9; 22) (q22; q12), resulting in a fusion protein EWS-NOR1, which activates NR4A3 target genes, for example PPAR-γ, and leads to oncogenesis(30)
CLINICAL-TRANSLATIONAL ADVANCES
NR4A Receptors: Identified Roles in Human Cancer
Altered NR4A receptor expression has been identified in many solid tumours, with a plethora of in vitro roles described. (Table 1) Meanwhile, reduced expression of NR4A1 and NR4A3 receptors is associated with haematological malignancies including acute myeloid leukaemia (AML), and chronic myelodysplastic/myeloproliferative disease. (31)
Novel Drug Targets
Drug development targeting NR4A receptor signalling is challenging due to the lack of a natural ligand, their bulky ligand binding domains, the diversity of their cell and context specific functions, and redundancy between members of the NR4A family. Despite these challenges, 
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Figure 1:
The NR4A receptors are involved in a myriad of cellular functions that contribute to cancer, including angiogenesis, apoptosis, metabolism, migration, proliferation and DNA repair. Expression of the NR4A receptors is induced by a variety of stimuli via multiple cell-signalling pathways including Protein Kinase A/CREB, NFκB, PI3K/AKT, JNK and MAP kinase pathways. 
